美国炎症性肠病少数族裔患者的COVID-19结局
本研究评估炎症性肠病(IBD)患者中COVID-19结局的种族和民族差异,以及非IBD合并症对差异的影响。研究关注少数族裔IBD合并COVID-19这一可能特别脆弱的人群。
要点
- 少数族裔IBD患者合并COVID-19可能尤为脆弱
- 需关注非IBD合并症对结局差异的影响
- 医疗可及性不平等可能介导不良结局
核心结论
- 少数族裔IBD合并COVID-19患者可能为特别脆弱人群,需评估结局差异及合并症影响
研究设计与样本
- 研究目的为评估IBD患者COVID-19结局的种族和民族差异及非IBD合并症的影响
临床怎么用
- 临床应关注少数族裔IBD合并COVID-19患者,并评估非IBD合并症对结局差异的作用
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The coronavirus disease 2019 (COVID-19) has affected more than 29 million people and led to more than 542,000 deaths in the United States.1 Older age, comorbidities, and racial and ethnic minority status are associated with severe COVID-19.2 Among patients with inflammatory bowel disease (IBD), racial and ethnic minorities have worse outcomes, mediated in part by inequitable health care access.3 Racial and ethnic minority patients with IBD and COVID-19 may be an especially vulnerable population. The purpose of this study was to evaluate racial and ethnic disparities in COVID-19 outcomes among IBD patients and the impact of non-IBD comorbidities on observed disparities.
引用
- Agrawal M, Brenner EJ, Yan Mak JW, et al. COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United States. Clin Gastroenterol Hepatol. 2021. PMID: 34089848. doi:10.1016/j.cgh.2021.05.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。